Apollo Endosurgery, Inc. (NASDAQ:APEN) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, APEN is expected to report 3Q20 loss of $ 0.21 per share from revenue of $ 9.98 million.
For the full year, analysts anticipate top line of $ 36.48 million, while looking forward to loss of $ 1.17 per share bottom line.
Previous Quarter Performance
Apollo Endosurgery, Inc. communicated loss for the second quarter of $ 0.30 per share, from the revenue of $ 5.64 million. The quarterly revenues fell 60.42 percent compared with the same quarter last year. Street analysts expected Apollo Endosurgery, Inc. to report loss of $ 0.33 per share on revenue of $ 5.19 million for the second quarter. The bottom line results beat street analysts by $ 0.03 or 9.09 percent, at the same time, top line results outshined analysts by $ 0.45 million or 8.67 percent.
Stock Performance
Shares of Apollo Endosurgery, Inc. traded up $ 0.02 or 1.12 percent on Wednesday, reaching $ 1.80 with volume of 3.20 thousand shares. Apollo Endosurgery, Inc. has traded high as $ 1.80 and has cracked $ 1.77 on the downward trend
The closing price of $ 1.80, representing a 43.55 % increase from the 52 week low of $ 1.24 and a 45.73 % decrease over the 52 week high of $ 3.28.
The company has a market capital of $ 42.62 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Apollo Endosurgery, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.apolloendo.com
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries.
